Avacta Group Plc is a healthcare company focused on developing innovative cancer drugs and in vitro diagnostics to improve human health and well-being. The company has two divisions: Therapeutics, which develops novel cancer therapies using proprietary platforms, and Diagnostics, which aims to develop market-leading diagnostic products.

Avacta Analytical

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. 

The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.

Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021.

By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies.

Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

Avacta

Dr. Fiona McLaughlin, Avatca's Chief Scientific Officer for Therapeutics, has written this summary of the poster presentations given at the recent International Conference on Molecular Targets and Cancer Therapeutics. 

https://lnkd.in/eSBdpF7j

Avacta's Chief Executive Officer Alastair Smith provides an accessible overview of the data in our AVA32 and AVA3996 posters, presented at the AACR-NCI-EORTC International Conference on Molecular Targets. https://lnkd.in/eJ76i2wz

Dr Fiona McLaughlin, Chief Scientific Officer, Therapeutics, at Avacta, spoke to Drug Discovery World magazine for their article 'Where is the drug discovery expertise happening in the UK?' She told them: “Avacta chose the life science cluster at Scale Space, in the White City Innovation District as the home of its Therapeutics HQ in 2022. A year on, and we can see the benefit of being a member of this thriving life science hub in London, that includes almost 200 life science companies. We have access to a huge talent pool from Imperial College and several other London Universities, and have completed a recruitment round to ensure we have access to cutting edge drug discovery in our labs.”

Download the magazine here: https://lnkd.in/gCywJhbt

Dr Fiona McLaughlin, Avacta Therapeutics Chief Scientific Officer, has contributed an article on 'The Future of #Oncology Innovation' to European Biopharmaceutical Review (EBR).

We will be in Boston next week to present positive new data at the International Conference on Molecular Targets and Cancer Therapeutics hosted by American Association for Cancer Research - National Cancer Institute (NCI) - EORTC - European Organisation for Research and Treatment of Cancer.

Find out more at: https://lnkd.in/eZYUVPaP 

We look forward to seeing you there!

#AVCT #Avacta #cancerresearch #oncology #innovation #drugdevelopment #precisionmedicine #immunotherapy

Congratulations to our colleagues at Launch Diagnostics Limited for winning best stand at the 2023 #IBMS Congress!

Good morning from IBMS Congress! Here is a first look at Launch’s Exibition Stand 2023, where we will be showcasing our diagnostic testing platforms-the VirClia Lotus for infectious diseases , BioCLIA 6500 for autoimmunity and the A15s for Faecal Calprotectin and Faecal Immunochemical testing. 

Launch Diagnostics specialises in Microbiology & Immunology diagnostics, including Antibiotic Susceptibility Testing.
For our full range of products please visit:

https://lnkd.in/d329Vfg 

Alternatively contact Rhian Fraser at RhianFraser@launchdiagnostics.com

We can’t wait to see you all at stand 615!

#biomedicalscience #biomedicalscientists #diagnostics #innovation #microbiology #immunology #virology #bacteriology #mycology #nhs #patients #patientcare

Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update. https://lnkd.in/eU6KAQvq

Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study. https://lnkd.in/eDvJ_ej8

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

COM:AVACTA

Avacta Group Plc

Last Close

72.00

30/08 15:44

Market Cap

2.71M

Beta: -

Volume Today

1.28M

Avg: -

Analysis Not Available